HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Marcello Carlo Ambrogi Marco Lucchi Franca Melfi Alfredo Mussi Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ambrogi, M. C. Articles by Mussi, A. Search for Related Content PubMed PubMed Citation Articles by Ambrogi, M. C. Articles by Mussi, A. Related Collections Lung - cancer

Eur J Cardiothorac Surg 2006;30:177-183
© 2006 Elsevier Science NL

Percutaneous radiofrequency ablation of lung tumours: results in the mid-term

^a Cardiac and Thoracic Department, Via Paradisa 2, 56124 Pisa, Italy
^b Department of Surgery, Via Paradisa 2, 56124 Pisa, Italy

Received 21 February 2006; received in revised form 23 March 2006; accepted 30 March 2006.

^_* Corresponding author. Tel.: +39 050 995211; fax: +39 050 577239. (Email: m.ambrogi{at}med.unipi.it).

Introduction: Radiofrequency ablation (RFA) of lung tumours has recently received much attention for the promising results achieved. Herein, we report the 5 years experience of a single referral centre in Europe, with particular reference to the mid-term results. Methods: Between October 2001 and June 2005, we performed 88 RFAs of lung tumours, 9 of which were followed by surgical resection. The remaining 79 RFAs, the object of this paper, were performed to treat 64 lesions in 54 patients: 39 males and 15 females with a mean age of 71.7 years (range of 51–89). All patients had clinical or pathological evidence of the neoplastic lesion, which was non-small cell lung cancer (NSCLC) in 40 cases and a metastasis in 24 cases. The mean size of the lesions was 2.4 cm (range of 1–5). Ten lesions were re-treated from one to as many as four times. The procedure was always performed under local anaesthesia and conscious sedation. A generator of RF with max power output of 200 W was utilised together with a needle with nine deployable electrodes, to achieve a target temperature of 90 °C that was maintained for 15–27 min according to the size of the lesions. Results: In all cases, except two, the procedure was technically successful. Morbidity consisted in 10 cases (12.7%) of partial pneumothorax, 1 haematoma of the chest wall and 1 pleural effusion. At a mean follow-up of 23.7 months (range of 6–50) we recorded a 61.9% of complete responses, with a higher rate in the metastatic lesions (70.8%) and in those smaller than 3 cm (69.7%). Mean (median) overall survival and local progression-free interval were 17.3 (28.9) months and 12.9 (24.1) months, respectively. Conclusions: Efficacy of RFA in the mid-term seems to settle at a promising level, with better results for metastatic lesions and, above all, for lesions smaller than 3 cm. Notwithstanding these encouraging results, RFA remains an alternative local therapy only when surgery cannot be performed, especially in NSCLC.

Key Words: Lung cancer • Pulmonary metastasis • Radiofrequency ablation • Percutaneous thermal ablation • Minimally invasive treatment

This article has been cited by other articles:

				J. C. Zhu, T. D. Yan, D. Glenn, and D. L. Morris Radiofrequency Ablation of Lung Tumors: Feasibility and Safety Ann. Thorac. Surg., April 1, 2009; 87(4): 1023 - 1028. [Abstract] [Full Text] [PDF]

				A. Pennathur, G. Abbas, I. Qureshi, M. J. Schuchert, Y. Wang, S. Gilbert, R. J. Landreneau, and J. D. Luketich Radiofrequency Ablation for the Treatment of Pulmonary Metastases Ann. Thorac. Surg., April 1, 2009; 87(4): 1030 - 1039. [Abstract] [Full Text] [PDF]

				R. Yoshimatsu, T. Yamagami, K. Terayama, T. Matsumoto, H. Miura, and T. Nishimura Delayed and Recurrent Pneumothorax After Radiofrequency Ablation of Lung Tumors Chest, April 1, 2009; 135(4): 1002 - 1009. [Abstract] [Full Text] [PDF]

				J. C. Zhu, T. D. Yan, and D. L. Morris A Systematic Review of Radiofrequency Ablation for Lung Tumors Ann. Surg. Oncol., June 1, 2008; 15(6): 1765 - 1774. [Abstract] [Full Text] [PDF]

				T. Hiraki, H. Gobara, T. Iishi, Y. Sano, T. Iguchi, H. Fujiwara, N. Tajiri, J. Sakurai, H. Date, H. Mimura, et al. Percutaneous radiofrequency ablation for clinical stage I non-small cell lung cancer: results in 20 nonsurgical candidates. J. Thorac. Cardiovasc. Surg., November 1, 2007; 134(5): 1306 - 1312. [Abstract] [Full Text] [PDF]

				P. F. Laeseke, T. M. Frey, C. L. Brace, L. A. Sampson, T. C. Winter III, J. R. Ketzler, and F. T. Lee Jr. Multiple-Electrode Radiofrequency Ablation of Hepatic Malignancies: Initial Clinical Experience Am. J. Roentgenol., June 1, 2007; 188(6): 1485 - 1494. [Abstract] [Full Text] [PDF]

				T. D. Yan, J. King, A. Sjarif, D. Glenn, K. Steinke, A. Al-Kindy, and D. L. Morris Treatment Failure After Percutaneous Radiofrequency Ablation for Nonsurgical Candidates With Pulmonary Metastases From Colorectal Carcinoma Ann. Surg. Oncol., May 1, 2007; 14(5): 1718 - 1726. [Abstract] [Full Text] [PDF]